


**SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND,
PREPARATION METHOD THEREFOR AND PHARMACEUTICAL
USE THEREOF**


5

ABSTRACT

A substituted heterocyclic fused cyclic compound as represented by formula (I)
or formula (IA) and having a selective inhibitory effect on KRAS gene mutation,
or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug
10 thereof, a pharmaceutical composition containing the compound, and an
application thereof in preparation of cancer drugs.



I



IA

Figure 1 accompanies.